Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1293187rdf:typepubmed:Citationlld:pubmed
pubmed-article:1293187lifeskim:mentionsumls-concept:C0023343lld:lifeskim
pubmed-article:1293187lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:1293187lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:1293187lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:1293187lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:1293187pubmed:issue12lld:pubmed
pubmed-article:1293187pubmed:dateCreated1993-4-7lld:pubmed
pubmed-article:1293187pubmed:abstractTextA gelatin particle agglutination assay for the detection of anti PGL-I antibodies in 40 clinically diagnosed and variously classified groups of leprosy cases revealed elevated PGL-I antibody titers in 85% of cases. In contrast, the slit-skin smear examination was positive in only 30% of cases. It was further observed that, out of 28 cases with Bacteriological Index (B.I.) zero, 22 cases (78.5%) had significant levels of PGL-I antibodies. There was no case in which the slit skin smear was positive and the PGL-I antibody titer was not significant. The elevated titers of PGL-I antibody better correlated (84%) with histopathological findings than did B.I. Thus it was concluded that estimation of PGL-I antibody titer is a better supplement to clinical diagnosis than B.I. Significant levels of PGL-I antibody were seen in 85% of cases who had no earlier chemotherapy or were treated for less than 2 months. Similar findings were observed in 12 patients who were on MDT for more than 5 months but for less than 2 years. In order to determine the significance of anti PGL-I antibodies in monitoring the response of patients to chemotherapy, a longer follow up with a greater number of cases should be contemplated.lld:pubmed
pubmed-article:1293187pubmed:languageenglld:pubmed
pubmed-article:1293187pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293187pubmed:citationSubsetIMlld:pubmed
pubmed-article:1293187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293187pubmed:statusMEDLINElld:pubmed
pubmed-article:1293187pubmed:monthDeclld:pubmed
pubmed-article:1293187pubmed:issn0385-2407lld:pubmed
pubmed-article:1293187pubmed:authorpubmed-author:SehgalV NVNlld:pubmed
pubmed-article:1293187pubmed:authorpubmed-author:PrakashKKlld:pubmed
pubmed-article:1293187pubmed:authorpubmed-author:AggarwalRRlld:pubmed
pubmed-article:1293187pubmed:issnTypePrintlld:pubmed
pubmed-article:1293187pubmed:volume19lld:pubmed
pubmed-article:1293187pubmed:ownerNLMlld:pubmed
pubmed-article:1293187pubmed:authorsCompleteYlld:pubmed
pubmed-article:1293187pubmed:pagination953-8lld:pubmed
pubmed-article:1293187pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:meshHeadingpubmed-meshheading:1293187-...lld:pubmed
pubmed-article:1293187pubmed:year1992lld:pubmed
pubmed-article:1293187pubmed:articleTitleSignificance of antibodies to phenolic glycolipid-I in leprosy diagnosis.lld:pubmed
pubmed-article:1293187pubmed:affiliationDepartment of Microbiology, Lady Hardinge Medical College, New Delhi, India.lld:pubmed
pubmed-article:1293187pubmed:publicationTypeJournal Articlelld:pubmed